"Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors" by Jeff P. Sharman

Selected Works of John M. Pagel, MD, PhD

Article

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

Blood (2014)

Jeff P. Sharman, Cancer Institute
Steven E. Coutre, Stanford University
Richard R. Furman, NewYork–Presbyterian Hospital
Bruce D. Cheson, Georgetown University
John M. Pagel, Fred Hutchinson Cancer Research Center
Peter Hillmen, St James's University Hospital
Jacqueline C. Barrientos, Cancer Institute
Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center
Thomas J. Kipps, University of California, San Diego
Ian W. Flinn, Cancer Institute
Paolo Ghia, Vita-Salute San Raffaele University
Michael Hallek, University of Cologne
Bertrand Coiffier, University of Lyon
Susan O'Brien, University of Texas MD Anderson Cancer Center
Eugen Tausch, University of Ulm
Karl-Anton Kreuzer, University of Cologne
Wendy Jiang
Mirella Lazarov
Daniel Li
Thomas M. Jahn, Children's Hospital Los Angeles
Stephan Stilgenbauer, University of Ulm

Link

Disciplines

Publication Date

December 6, 2014

Citation Information

Jeff P. Sharman, Steven E. Coutre, Richard R. Furman, Bruce D. Cheson, et al.. "Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors" Blood Vol. 124 Iss. 21 (2014) p. 330 - 330
Available at: http://works.bepress.com/john-pagel/88/